AGO1 and ovarian carcinoma: To further confirm the roles of ERK1/2 downstream of AGO1 in SKOV3 cells, ERK inhibitor LY3214996 or P38 inhibitor SB203580 was treated to investigate the changes of ovarian cancer cell functions.